EANS-News: Symrise AG and Probi sign joint research and development agreement
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Subtitle: Bundling of expertise in developing new product solutions in the
areas of
food and beverages, cosmetics, dietary supplements and pharmaceuticals
Initial focus on oral care applications with proven health benefits
Expanded know-how for accelerated product development in dynamic market
segments
Company Information
Holzminden, December 20, 2012 (euro adhoc) - The German Symrise AG, a leading
manufacturer of flavors, fragrances, cosmetics and health ingredients, and the
probiotics company Probi AB based in Lund, Sweden, have signed a joint research
and development agreement.
In response to the growing need for turn-key product solutions with proven
health benefits, both companies today announced their plans to collaborate on
innovative projects such as in oral health applications.
"For Symrise the agreement with Probi is a logical step which, going forward,
allows us to meet the growing demand for functional consumer health products
even better. Both, in established markets as well as emerging markets, consumers
become more and more sensitive to healthy nutrition and a balanced way of life.
The highly complementary competencies and strategic innovation agendas of Probi
and Symrise will allow us to support our joint customers in their development
and marketing efforts, and to grow at an accelerated pace", stated Dr.
Heinz-Jürgen Bertram, CEO of Symrise AG.
Symrise has expertise in the research, development and manufacturing of food,
beverages, cosmetics and pharmaceutical products and sees increasing potential
in the health benefits of probiotics. The company combines the ability and the
network to perform efficacy screening with the necessary know-how of applying
active ingredients. Moreover Symrise holds a globally leading position in the
area of oral care.
Probi is a trailblazing company that is highly reputed in the research,
development and manufacturing of probiotics. It sells some of the most effective
gut and immune health probiotics available on the world market. Expanding into
new areas such as oral health will offer additional growth prospects for the
company.
"The globally recognized know-how of Symrise in sensory, active ingredients and
applications combined with Probi's long-standing and proprietary expertise in
patented probiotics will allow us to develop new consumer products with real
health benefits and sensory profiles without compromises," added Michael
Oredsson, CEO of Probi AB.
Symrise AG currently holds a 14.97% minority share of Probi and may increase
this stake in the future. The company is listed on the NASDAQ OMX Nordic
exchange in Stockholm.
About Symrise
Symrise is a global supplier of fragrances, flavorings, cosmetic active
ingredients and raw materials as well as functional ingredients. Its clients
include manufacturers of perfumes, cosmetics and foods, the pharmaceutical
industry and producers of nutritional supplements.
Its sales of EUR1.584 billion in 2011 place Symrise among the top four in the
global flavors and fragrances market. Headquartered in Holzminden, Germany, the
Company is represented in over 35 countries in Europe, Asia, the United States
and Latin America.
Symrise works with its clients to develop new ideas and market-ready concepts
for products that form an indispensable part of everyday life. In doing so,
Symrise combines its insights into consumer trends with cutting-edge
technologies, focusing on innovative trend and lifestyle products that have
additional practical value for the consumer. www.Symrise.com
About Probi
Probi is a leading player in the probiotic research and the development of
efficient and well-documented probiotics. The research areas include:
gastrointestinal tracts, immune system, metabolic syndrome and stress and
recovery. Probi's customers are leading companies in the functional foods and
consumer healthcare business areas. Total income for 2011 was MSEK 95.0.
Probi's share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has
approximately 4,500 shareholders. www.probi.com.
Contact:
Symrise AG
Bernhard Kott
Phone: +49 (0)5531 90-1721
E-mail: bernhard.kott@symrise.com
Probi AG
Michael Oredsson
Phone: +46 46 286 23
E-mail: michael.oredsson@probi.se
Further inquiry note:
Pressekontakt
Bernhard Kott
Tel. +49 (0)5531 90-1721
bernhard.kott@symrise.com
Phone: +46 46 286 23
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Symrise AG
Mühlenfeldstraße 1
D-37603 Holzminden
phone: +49 (0) 5531/90-0
FAX: +49 (0) 5531/90-1649
mail: ir@symrise.com
WWW: http://www.symrise.com
sector: Chemicals
ISIN: DE000SYM9999
indexes: MDAX
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English